Targets › KRT5
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Jan 2027.
Structural component of intermediate filaments in basal keratinocytes of stratified epithelia. Forms heteropolymers with type I partners including KRT14 and KRT15, contributing to the formation of the keratin intermediate filament network that provides mechanical stability and resilience to the basal layer of the epidermis. (UniProt, P13647)
Open in Phaseline: the race on KRT5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BioMendics | TolaSure Topical Gel Topical agent targeting aggregated mutant keratin | KRT5 | Phase 2 | Epidermolysis Bullosa Simplex | Jan 2027 |
Epidermolysis Bullosa Simplex (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.